Want to see GB:GENI full AI Analyst Report?
GENI Stock Chart & Stats
0.90 p
0.03 p(3.13%)
At close: 4:00 PM EDT
0.90 p
0.03 p(3.13%)
Day’s Range― - ―
52-Week Range0.75 p - 5.50 p
Previous CloseN/A
Volume512.05K
Average Volume (3M)2.90M
Market Cap
£6.40M
Enterprise Value6.14 p
Total Cash (Recent Filing)£895.00K
Total Debt (Recent Filing)£146.00K
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume2,913,023
30 Day Avg. Volume2,900,870
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.70M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthAccelerating revenue growth indicates improving commercial traction and a larger base from which the company can develop operating scale. If this trend persists, stronger sales should help absorb fixed costs, support investment in the diagnostics platform, and improve future earnings potential.
Gross Margin ExpansionHigher gross margin shows that a greater share of revenue is retained after direct costs, strengthening the economics of each additional sale. Sustained margin improvement could provide operating leverage over time, although the current cost base still prevents profitability.
Limited Absolute DebtA relatively small absolute debt burden reduces the immediate pressure from principal repayment and interest obligations compared with a heavily indebted business. This gives management some financial flexibility, even though equity erosion and continuing losses remain significant constraints.
Bears Say
Deep And Persistent LossesSevere and recurring losses show that current revenue scale is not covering the company’s operating cost base. Continued unprofitability can consume capital, restrict investment capacity, and make the path to sustainable earnings dependent on substantial operational improvement.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business is not yet funding itself through operations. Continued cash burn can require external financing or tighter spending, limiting strategic flexibility and increasing the consequences of any delay in reaching cash breakeven.
Material Equity ErosionThe sharp reduction in equity materially weakens the balance sheet and leaves less capital available to absorb further losses. If negative earnings continue, financial flexibility may deteriorate further, making funding needs more pressing despite the company’s modest absolute debt.
GENinCode UK Ltd. News
GENI FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
GENinCode UK Ltd. lowest share price was 0.75 p and its highest was 5.50 p in the past 12 months.
What is GENinCode UK Ltd.’s market cap?
GENinCode UK Ltd.’s market cap is £6.40M.
When is GENinCode UK Ltd.’s upcoming earnings report date?
GENinCode UK Ltd.’s upcoming earnings report date is Sep 30, 2026 which is in 10 days.
How were GENinCode UK Ltd.’s earnings last quarter?
GENinCode UK Ltd. released its earnings results on Jun 08, 2026. The company reported -0.01 p earnings per share for the quarter.
Is GENinCode UK Ltd. overvalued?
According to Wall Street analysts GENinCode UK Ltd.’s price is currently Overvalued.
Does GENinCode UK Ltd. pay dividends?
GENinCode UK Ltd. does not currently pay dividends.
What is GENinCode UK Ltd.’s EPS estimate?
GENinCode UK Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GENinCode UK Ltd. have?
GENinCode UK Ltd. has 753,041,140 shares outstanding.
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
GENinCode UK Ltd. reported an EPS of -0.01 p in its last earnings report. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
Currently, no hedge funds are holding shares in GB:GENI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.